61
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

, , , &
Pages 173-179 | Published online: 01 Mar 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Leonardo Calza, Matteo Cafaggi, Vincenzo Colangeli, Marco Borderi, Enrico Barchi, Massimiliano Lanzafame, Stefano Nicole’, Anna Maria Degli Antoni, Isabella Bon, Maria Carla Re & Pierluigi Viale. (2018) Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy. Infectious Diseases 50:5, pages 352-360.
Read now
Barbara Rossetti, Francesca Montagnani & Andrea De Luca. (2018) Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. Expert Opinion on Pharmacotherapy 19:7, pages 713-738.
Read now
Umberto Restelli, Massimiliano Fabbiani, Simona Di Giambenedetto, Carmela Nappi & Davide Croce. (2017) Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial. ClinicoEconomics and Outcomes Research 9, pages 569-571.
Read now
Vicente Soriano, Jose Vicente Fernandez-Montero, Laura Benitez-Gutierrez, Carmen de Mendoza, Ana Arias, Pablo Barreiro, José M. Peña & Pablo Labarga. (2017) Dual antiretroviral therapy for HIV infection. Expert Opinion on Drug Safety 16:8, pages 923-932.
Read now

Articles from other publishers (5)

Kevin M Gibas, Sean G Kelly, Jose R Arribas, Pedro Cahn, Chloe Orkin, Eric S Daar, Paul E Sax & Babafemi O Taiwo. (2022) Two-drug regimens for HIV treatment. The Lancet HIV 9:12, pages e868-e883.
Crossref
Mariantonietta Pisaturo, Lorenzo Onorato, Antonio Russo, Salvatore Martini, Paolo Chiodini, Simona Signoriello, Paolo Maggi & Nicola Coppola. (2021) Risk of failure in dual therapy versus triple therapy in naïve HIV patients: a systematic review and meta-analysis. Clinical Microbiology and Infection 27:1, pages 28-35.
Crossref
Cristina Mussini, Patrizia Lorenzini, Alessandro Cozzi-Lepri, Giulia Marchetti, Stefano Rusconi, Andrea Gori, Silvia Nozza, Miriam Lichtner, Andrea Antinori, Andrea Cossarizza & Antonella d’Arminio Monforte. (2018) Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Medicine 16:1.
Crossref
Massimiliano Fabbiani, Roberta Gagliardini, Nicoletta Ciccarelli, Eugenia Quiros Roldan, Alessandra Latini, Gabriella d’Ettorre, Andrea Antinori, Antonella Castagna, Giancarlo Orofino, Daniela Francisci, Pierangelo Chinello, Giordano Madeddu, Pierfrancesco Grima, Stefano Rusconi, Barbara Del Pin, Francesca Lombardi, Alessandro D’Avino, Emanuele Focà, Manuela Colafigli, Roberto Cauda, Simona Di Giambenedetto, Andrea De Luca, R Cauda, S Di Giambenedetto, M Fabbiani, A Mondi, N Ciccarelli, A Borghetti, E Baldonero, S Belmonti, A D’Avino, R Gagliardini, S Lamonica, F Lombardi, L Sidella, E Tamburrini, E Visconti, A De Luca, A Giacometti, F Barchiesi, P Castelli, O Cirioni, S Mazzocato, M Di Pietro, P Blanc, A Degli Esposti, B Del Pin, E Mariabelli, S Marini, A Poggi, E Quiros Roldan, E Focà, S Amadasi, A Apostoli, L Biasi, A Bonito, N Brianese, S Compostella, A Ferraresi, D Motta, M T Mughini, B M Celesia, M Gussio, S Sofia, P Grima, M Tana, P Tundo, C Viscoli, L De Hoffer, A Di Biagio, S Grignolo, A Parisini, E Schenone, L Taramasso, P E Manconi, A Boccone, F Ortu, P Piano, L Serusi, M Puoti, M C Moioli, R Rossotti, G Travi, F Ventura, M Galli, S Rusconi, S Di Nardo Stuppino, V Di Cristo, A Giacomelli, V Vimercati, P Viale, A Gori, G Rizzardini, A Capetti, L Carenzi, F Mazza, P Meraviglia, S Rosa, P Zucchi, M Mineo, A Latini, M Colafigli, M Giuliani, A Pacifici, F Pimpinelli, F Solivetti, F Stivali, A Antinori, F Angelici, R Bellagamba, D Delle Rose, R Fezza, R Libertone, S Mosti, P Narciso, E Nicastri, S Ottou, C Tomassi, C Vlassi, M Zaccarelli, F Zoppè, V Vullo, G D’Ettorre, F Altavilla, G Ceccarelli, A Fantauzzi, S Gebremeskel, S Lo Menzo, I Mezzaroma, F Tierno, N Petrosillo, P Chinello, E Boumis, S Cicalini, E Grilli, M Musso, C Stella, M S Mura, G Madeddu, P Bagella, M Mannazzu, V Soddu, P Caramello, G Orofino, C Carcieri, S Carosella, M Farenga, P G Scotton, M C Rossi, E Concia, F Corsini, C Gricolo, M Lanzafame, E Lattuada, S Leonardi, F Rigo, A Lazzarin, A Castagna, A Bigoloni, E Carini, S Nozza, V Spagnuolo, D Francisci, B Belfiori, L Malincarne, E Schiaroli, C Sfara, A Tosti, D Sacchini, A Ruggieri & C Valdatta. (2018) Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. Journal of Antimicrobial Chemotherapy 73:7, pages 1955-1964.
Crossref
Erika G. MartinEli S. RosenbergDavid R. Holtgrave. (2018) Economic and Policy Analytic Approaches to Inform the Acceleration of HIV Prevention in the United States: Future Directions for the Field. AIDS Education and Prevention 30:3, pages 199-207.
Crossref